PYPD today

$6.40-$0.20 (-3.03%)close Nov 12, 2026

Trend

DailyUptrend (confirmed)

4 hourLeaning Bearish

1 hourStrong Bearish

15 minSymmetric Triangle

5 minStrong Bearish

Daily trend turns down below $5.27

Key levels

Resistance$7.00

Resistance$6.48

Support$5.84

Support$5.27

About PolyPid

PolyPid is a clinical-stage pharmaceutical company developing a drug delivery technology called PLEX. Its main experimental product, D-PLEX 100, is designed to prevent infections at surgical sites in patients having colorectal operations. The company is based in Israel and also has operations in the United States, and no product has received regulatory approval yet.

Based on the company's 20-F filed Feb 25, 2026.

Nasdaq · Healthcare

PolyPid Ltd. (PYPD)

$6.40-0.20 (-3.03%)

WATCHLISTGrade: BRisk: LOW

1D 5D1M1Y 5Y MaxSign up for all timeframes

High6.97

Low6.33

Open6.74

Volume183K

Avg Vol141K

VWAP6.49

30d High6.60

30d Low4.72

30d Chg+23.31%

See full chart with real-time data

What Is the Price Target for PYPD?

SEPT Low Target

$10.00

SEPT Mid Target

$11.50

SEPT High Target

$13.00

Analyst Consensus

$11.50

Current: $6.60Upside: +74.2%Confidence: 40%Method: Analyst Consensus

Is PYPD a Buy or Sell Right Now?

Investability Score

WATCHLIST12-18 months

News summary · last 30 days

Nov 11▼ DownEarnings2 articles

PolyPid shares closed at $6.60, down 1.20% on the day, after trading in a wide range between $6.18 and $7.15 on volume of 414,965. The move followed the company's third-quarter 2026 earnings call, in which PolyPid reported a quarterly loss of $0.24 per share, wider than the $0.06 loss analysts had expected. The larger-than-anticipated loss is a bearish signal for the stock, though the day's modest decline suggests the miss was partly absorbed by the market. Overall, the earnings news points to downward pressure in the near term.

Thesis

AI-Powered Trading Signals

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for PYPD.

Start Free Trial →

Is PYPD Overvalued or Undervalued?

Valuation Verdict

OVERVALUED

Methods Used

P/E Forward, PEG, Analyst Consensus

Fair Value

$8.06

Moat Score

NONE

2/9

Piotroski Score

N/A

Altman Z-Score

What Is Smart Money Doing with PYPD?

Insider Signal

NEUTRAL

0 buys / 0 sells (90d)

Congress Signal

NEUTRAL

0 buys / 0 sells (90d)

Institutional

N/A

Short Squeeze Risk

LOW

Signal: NEUTRAL

Track Smart Money Across 4,000+ Stocks

Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.

See All Smart Money Signals →

PYPD Growth Story

Revenue YoY

N/A%

3yr Revenue CAGR

N/A%

EPS Growth YoY

-57.43%

FCF Growth YoY

-27.4%

Revenue Trend

UNKNOWN

Dark Pool Trades for PYPD

PREVIEW

SEPT Investing tracks real-time dark pool institutional trades for PYPD, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.

Time	Price	Size	Value	Side
19:48:41	$6.38	1,000	$$6K	SELL
19:48:07	$6.37	1,000	$$6K	SELL
19:07:28	$6.39	3,200	$$20K	BUY
19:07:28	$6.35	2,080	$$13K	SELL
18:51:58	$6.45	2,000	$$13K	MIDPOINT

5 dark pool trades shown · $$59K preview volume

Real-time institutional flow, block trades, and net positioning

See all dark pool activity

Full AI Research Report

SEPT's Trading AI has generated a free, downloadable PDF research report for PolyPid Ltd. (PYPD) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.

Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...

AI-Powered Trading Signals.

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.

Try SEPT Free for 7 Days →

PYPD — frequently asked questions

What is PYPD stock price today?

PolyPid Ltd. (PYPD) is at $6.40, down 3.03% (-$0.20) at the Nov 12, 2026 close.

Why is PYPD stock down today?

Nov 11, 2026: PolyPid shares closed at $6.60, down 1.20% on the day, after trading in a wide range between $6.18 and $7.15 on volume of 414,965. The move followed the company's third-quarter 2026 earnings call, in which PolyPid reported a quarterly loss of $0.24 per share, wider than the $0.06 loss analysts had expected.

What is the PYPD price target?

The average analyst price target for PYPD is $11.50, ranging from $10 to $13, based on 2 analysts. Latest: Oppenheimer upgrade on Oct 28, 2026.

What do analysts rate PYPD?

Analyst ratings for PYPD: 1 Buy, 1 Hold, 0 Sell — consensus Hold.

Did PYPD beat earnings?

PYPD last reported on Aug 12, 2026: EPS -$0.35 vs -$0.38 expected — a beat of 7.3%.

What is PYPD's P/E ratio?

PYPD trades at a P/E of 3.0 vs a Healthcare average of 17.2.

Does PYPD pay a dividend?

PYPD does not currently pay a dividend.

What are PYPD support and resistance levels?

Support: $5.84, $5.27, $4.61. Resistance: $6.48, $7.00, $7.50.

What are insiders doing with PYPD?

Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.

What is the latest news on PYPD?

Nov 12, 2026: HC Wainwright Reiterates Buy Rating on PolyPid With $13 Price Target · Nov 12, 2026: PolyPid Posts Q3 2026 Results, Issues Business Update · Nov 11, 2026: PolyPid holds Q3 2026 earnings call